This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (19)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Critical Care/ Intensive Care Medicine  • Critical Care Medicine, Other  • Hematology/ Hematologic Malignancies  • Hematology, Other  • Immunology  • Immunology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Howard L. Corwin, MD; James P. AuBuchon, MD

JAMA. 2003;289:1993-1995.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

For most of the last half-century, blood transfusion has been looked upon as relatively "risk free" and with obvious clinical benefit.¹ A dramatic change in thinking occurred in the early 1980s, when concerns about transfusion-related infections, particularly those caused by hepatitis C virus and the human immunodeficiency virus (HIV), prompted reevaluation of the risks of allogeneic transfusion. Advances in transfusion medicine have greatly decreased the risk of viral transmission through blood transfusion; however, the approach to blood transfusion continues to be directed toward achieving a zero-risk blood supply.² Over the last several years attention has focused on the advisability of the universal application of leukoreduction to the blood supply.

Leukoreduction of blood has several widely accepted applications. It is well established that leukoreduction will reduce the risk of HLA alloimmunization, an important benefit in patients who are likely to receive multiple transfusions . . . [Full Text of this Article]

Author Affiliations: Departments of Anesthesiology (Dr Corwin), Medicine (Drs Corwin and AuBuchon), and Pathology (Dr AuBuchon), Dartmouth-Hitchcock Medical Center, Lebanon, NH.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Clinical Outcomes Following Institution of the Canadian Universal Leukoreduction Program for Red Blood Cell Transfusions
, , , , , , , , , , , , , and
JAMA. ;289():1941-1949.
FULL TEXT  

Clinical Outcomes Following Institution of Universal Leukoreduction of Blood Transfusions for Premature Infants
, , , , , , , and
JAMA. ;289():1950-1956.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Understanding the Consequences of Transfusion-Related Acute Lung Injury
Shander and Popovsky
Chest 2005;128:598S-604S.
ABSTRACT | FULL TEXT  

West Nile Virus
Katz et al.
NEJM 2003;349:1873-1874.
FULL TEXT